That dollar amount is 51 percent of the money in all U.S. sector-focused ETFs, and it is coming in at the fastest rate in six years, according to the report.
Nine of the top ten largest holdings in three sector funds are drug and biotech companies, according to the report.
Forecasters thought the Patient Protection and Affordable Care Act and patent issues would have slowed this sector, but this has proved to not be the case.
“The big pharmas are managing through [patent issues] really well and they have pipelines that look better than people were thinking,” said Tony Scherrer, director of research at Smead Capital Management, in the report.
More Articles on Pharmaceuticals:
Pharmaceutical Companies Spending Less on Promotional Drug Speakers
Hepatitis C Drug Costs More Than 1K a Pill
Pacira Pharmaceuticals Becomes NPSF Coalition Member
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
